Observational studyAlcohol, clinical & experimental research2025
Alcohol-associated liver disease is associated with less adverse outcomes compared to nonalcohol-associated liver disease in patients with COVID-19.
Observational study in Alcohol, clinical & experimental research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Alcohol-associated liver disease is associated with less adverse outcomes compared to nonalcohol-associated liver disease in patients with COVID-19.Alcohol, clinical & experimental research · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA multicenter cohort of patients hospitalized with COVID-19 was examined to consider the impact of comorbid liver disease in general, and alcohol-associated liver disease (ALD) in particular, on short-term outcomes.
methodsData from patients with COVID-19 hospitalized at 21 participating healthcare systems between February 2020 and January 2022 were examined. The analyses used generalized linear mixed model logistic regression including random intercepts to account for clustering within healthcare systems.
resultsAmong 145,944 patients hospitalized with COVID-19, 7951 (5.4%) had comorbid liver disease; 1153 (14.5%) had ALD, and 6798 (85.5%) had nonalcohol-associated liver disease (NAALD). The presence of liver disease was associated with increased mortality (adjusted odds ratio [aOR] 3.39, p < 0.001), assisted ventilation (aOR 2.95, p < 0.001), and ICU admission (aOR 2.27, p < 0.001). There was a clear gradient of mortality among the severity of liver disease such that fibrosis < cirrhosis < decompensated cirrhosis. When compared to patients with NAALD, ALD was associated with reduced mortality (aOR 0.36, p < 0.001), assisted ventilation (aOR 0.38, p < 0.001), and ICU admission (aOR 0.56, p < 0.001). On multivariable analysis, liver disease, male gender, increasing age, higher BMI, and former smoking status, but not ALD, were associated with increased mortality with COVID-19.
conclusionsIn this large cohort of hospitalized COVID-19 patients, the presence of liver disease increased the odds of all tested adverse outcomes with a mortality gradient that correlated with the severity of liver disease. When compared to liver disease not related to alcohol, ALD was associated with reduced odds of mortality, assisted ventilation, and ICU admission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.